Cochrane · systematic review · CD012556
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
Goldkuhle, M, Dimaki, M, Gartlehner, G, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Nivolumab compared to no other intervention for adults with Hodgkin's lymphomas
Population: adults with Hodgkin's lymphoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OS Nivolumab vs no other intervention | no estimate extracted | 2 studies · 260 participants | Very low |
QoL Nivolumab vs no other intervention | no estimate extracted | 1 study · 80 participants | Very low |
PFS Nivolumab vs no other intervention | no estimate extracted | 3 studies · 283 participants | Very low |
Response rate Nivolumab vs no other intervention | no estimate extracted | 3 studies · 283 participants | Very low |
Treatment‐related mortality Nivolumab vs no other intervention | no estimate extracted | NR | No studies |
Grade 3 or 4 AEs Nivolumab vs no other intervention | no estimate extracted | 3 studies · 283 participants | Very low |
SAEs Nivolumab vs no other intervention | no estimate extracted | 1 study · 243 participants | Very low |